Sign in
Not yet recruitingPhase 3

A Double-Blind, Placebo-Controlled Study of Nebulized Bacteriophages in Patients With Ventilator-Associated Pneumonia Due to Pseudomonas Aeruginosa

Key facts

Who runs it
Assistance Publique - Hôpitaux de Paris
Where
France10 sites in 1 countryChoose a country to see its sites
Status
Not yet recruiting
Phase
Phase 3
People taking part
184 people, planned
Started
3 Nov 2026
Expected to end
3 Jan 2030
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Bacteriophages GMP
  • saline solution (placebo)
Record updated
4 September 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Patients ≥ 18 years old
  • Intubated and mechanically ventilated for at least 48 hours
  • Mechanical ventilation expected to continue for at least 3 days
  • Clinical diagnosis of VAP
  • VAP due to P. aeruginosa (P. aeruginosa recovered at a significant level from lung sample (≥10\^4/ml for BAL or ≥10\^5/ml for tracheal aspirate or ≥10\^3 CFU/ml for plugged telescopic catheter)
  • Signed informed consent from the patient or the patient's legal representative or a family member or a close relative. According to the legal conditions of emergency inclusion, randomization without the family member or the surrogate consent could be performed if the patient is unable to give his/her consent and if no legal representative/family member or close relative is present. Close relative/ legal representative/family member consent will be asked as soon as possible. The patient will be asked to give his/her consent for continuation of the trial when his/her condition will allow
  • Patient with childbearing potential* should have reliable contraception for the all duration of the study
  • Affiliation to social security (AME excluded)

Who cannot take part

  • Participation in another interventional study evaluating drugs for VAP or being in the exclusion period following the end of a previous interventional study evaluating drugs for VAP
  • Patients with cystic fibrosis, lung cancer, lung resection, known bronchial obstruction, or active tuberculosis
  • Severe hypoxemia as defined by PaO2/FiO2 < 100 mmHg, except if the patient is on ECMO (extracorporeal membrane oxygenation)
  • Impossibility to set a tidal volume of 6 ml/kg of ideal body weight during nebulization without risk of barotrauma
  • Patient not expecting to survive 48 hours after randomization
  • Polymicrobial VAP (presence of pathogens other than P. aeruginosa at a significant level in lung samples (≥10\^4/ml for BAL or ≥10\^5/ml for tracheal aspirate). If the culture retrieves oropharyngeal flora, even at a significant threshold, in addition to Pseudomonas aeruginosa, the patient is eligible
  • Contraindication to nebulization
  • Pregnancy or breastfeeding
  • Patients under guardianship or curatorship

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Ventilator-associated pneumonia (VAP) complicates the hospital course of up to 40% of mechanically ventilated patients and is associated with mortality rates approaching 30%, despite appropriate antibiotic therapy (ATB). Gram-negative bacteria account for approximately 60% of VAP episodes, with Pseudomonas aeruginosa (Pa) being one of the most common pathogens. Recurrent Pa-VAP occurs in 19-33% of cases outside the COVID-19 setting, whereas recurrence rates as high as 79% have been reported in patients with COVID-19, most often caused by the same pathogen and frequently occurring despite adequate antibiotic therapy.

Read full original descriptionShow less

Several attempts have been made to improve pulmonary antibiotic exposure by combining intravenous therapy with aerosolized antibiotics delivered through conventional nebulizers. However, clinical results have been disappointing, largely because standard jet nebulizers deliver less than 10% of the nominal dose to the lungs owing to high residual volumes, drug deposition within the ventilator circuit and endotracheal tube, and loss through the expiratory limb. Even with more efficient vibrating mesh nebulizers, two recent randomized con-trolled trials failed to demonstrate any clinical benefit of adjunctive nebulized antibiotics in patients with Gram-negative VAP.

Bacteriophages are bacteria-specific viruses that have emerged as a promising therapeutic alternative for difficult-to-treat bacterial infections. Their highly specific host range allows selective targeting of pathogenic bacteria while sparing the commensal microbiota and human cells, thereby minimizing toxicity and off-target effects. An increasing body of preclinical evidence and clinical case reports supports the safety and potential efficacy of anti-P. aeruginosa phage therapy. More recently, a porcine model of Pa-VAP demonstrated that high concentrations of bacteriophages can be efficiently delivered to the lungs by nebulization during mechanical ventilation, resulting in rapid control of the pulmonary infection. The use of phages as compassionate treatment has been authorized in September 2021 in this indication using phages produced by Phagenix- ©.

The aim of this placebo controlled study is to demonstrate the efficacy and safety of nebulized anti-Pa bacteriophages, delivered to the lung using a vi-brating mesh nebulizer, in addition to conventional IV ATB treatment.

The 2 groups in the trial

  • Bacteriophages GMPTreatment being tested

    Nebulization of bacteriophages PP1450, PP1777, PP1792 and PP1797 will be performed using a vibrating mesh nebulizer (Aerogen). The aerosol generator will be placed upstream of the heated humidifier, which will remain active during administration. The nebulizer chamber will be filled immediately prior to dosing. When clinically feasible, mechanical ventilation settings will be standardized (volume-controlled mode, tidal volume 6-8 mL/kg ideal body weight, respiratory rate 16-20/min, inspiratory flow \<40 L/min), with no specific adjustments for PEEP or FiO₂. Sedation may be used to minimize patient-ventilator asynchrony. Nebulization is expected to last approximately 45-60 minutes. These settings are recommended but not mandatory.

  • Saline solutionPlacebo, for comparison

    Nebulization of saline solution will be performed using a vibrating mesh nebulizer (Aerogen). The aerosol generator will be placed upstream of the heated humidifier, which will remain active during administration. The nebulizer chamber will be filled immediately prior to dosing. When clinically feasible, mechanical ventilation settings will be standardized (volume-controlled mode, tidal volume 6-8 mL/kg ideal body weight, respiratory rate 16-20/min, inspiratory flow \<40 L/min), with no specific adjustments for PEEP or FiO₂. Sedation may be used to minimize patient-ventilator asynchrony. Nebulization is expected to last approximately 45-60 minutes. These settings are recommended but not mandatory.

    Treatment: saline solution (placebo)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
4 September 2026